NCT00019383View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 1998

Study Completion Date

June 30, 2003

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

aldesleukin

BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

sargramostim

BIOLOGICAL

tyrosinase peptide

BIOLOGICAL

tyrosinase-related protein-1

Trial Locations (1)

20892

Surgery Branch, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00019383 - Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma | Biotech Hunter | Biotech Hunter